Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 2Colonic Neoplasms 2Neoplasms, Glandular and Epithelial 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Liver Neoplasms 1Liver Diseases 1Digestive System Neoplasms 1Digestive System Diseases 1Carcinoma, Hepatocellular 1Carcinoma 1Adenocarcinoma 1

Interventions

Gemcitabine 4pembrolizumab 3napabucasin 3Irinotecan 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3lenvatinib 2entinostat 2Taxes 2Sunitinib 2Sorafenib 2Paclitaxel 2Leucovorin 2Fluorouracil 2Cisplatin 2Bevacizumab 2pralsetinib 1linifanib 1durvalumab 1Radiofrequency Ablation 1Pemetrexed 1Nivolumab 1Immunotherapy 1Endoscopic Mucosal Resection 1Cobicistat 1Chemoradiotherapy 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Glandular and Epithelial × linifanib × Gastrointestinal × Clear all
NCT01009593 2012-09-10

Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

Abbott

Phase 3 Terminated
1,035 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡